Braveheart Bio, Inc. (BRVE), a clinical-stage biopharmaceutical company focused on therapies for hypertrophic cardiomyopathy (HCM) and other cardiovascular diseases, is launching an initial public offering of 18,750,000 shares of common stock at an estimated price range of $15.00–$17.00 per share. The stock is expected to list on the Nasdaq Global Market under the symbol “BRVE”, with underwriters holding a 30‑day option to purchase up to 2,812,500 additional shares.
At an assumed IPO price of $16.00, Braveheart estimates net proceeds of about $274.5 million (or $316.4 million with full option exercise), increasing pro forma cash and cash equivalents from $80.6 million to $355.1 million. Shares outstanding after the offering would be 70,652,838 (or 73,465,338 with full option exercise). Proceeds, together with existing cash, are earmarked primarily to fund global Phase 3 trials of lead cardiac myosin inhibitor BHB‑1893 in obstructive and non‑obstructive HCM, related R&D personnel and infrastructure, and general corporate purposes.
Braveheart reported a net loss of $66.1 million in 2025 and $14.3 million for the three months ended March 31, 2026, with an accumulated deficit of $80.3 million as of that date. The company qualifies as an emerging growth company and a smaller reporting company. A cornerstone investor has provided a non‑binding indication of interest to purchase up to $75 million of shares, and up to 5% of the offering is reserved for a directed share program.